TO THAT

PTO/S8/08a/b (08-03)

Approved for use through 07/31/2009, OMB 0851-0001
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

stitute for form 1448A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

Complete If Known				
Application Number	10/623,378			
Filing Date	July 18, 2003			
First Named Inventor	Jay D. KRANZLER			
Art Unit	1614			
Examiner Name	Rebecca COOK			
Attorney Docket Number	20269/1201776-US3			

U.S. PATENT DOCUMENTS					
Examiner thitials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

1

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	No. 1 Country Code 3-Numb	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,		
		Country Code ³ -Number ⁴ -Kind Code ³ (if known)	Date MM-DD-YYYY	Applicant of Olland Decument	Where Retevant Passages or Relevant Figures Appear	Τ°	
	BA S	WO 02/053149-A2	07/11/2002	Pharmacia & Upjohn Co.		П	
		WO 00/32178	06/08/2002	Mueller / 2)	DAM ANDLINE	П	
		EP 0 759 299 B1	04/26/2000	Eti Lilly and Company		\neg	
	BD	WO 99/59593		Eli Lilly and Company	meille	7	
	BE	FR 2.752-732	03/06/1998	Bruno et al.		П	
	BF	WO 97/35584	10/02/1997	Eli Lilly and Company		П	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional). "See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (boo magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	k.	T²
*	CA	RAQ et al., The neuropharmacology of centrally-acting analgesic medications in fibromyalgia Theum. Qis. Clin. N. Am. 28 (2002) 235-259.		
. (СВ	NINAN, M.D., Philip T., Use of Ventafaxine in Other Psychlatric Disorders, Depression and Anxiety 12(1) (2009) 90-94	0	P
	CC	NUTT et al., Potential Applications of Venlafaxine, Rev. Contemp. Pharmacother. 9 (1998) 321-331.	1	V
13.1	CD	DWIGHT et al., An Open Clinical Trial of Venlafaxine Treatment of Fibromyalgia, Psychsomatics 39(1) (1998) 14-17.	7	
1	CE	GOODNICK et al., Psychotropic Treatment of Chronic Fatigue Syndrome and Related Disorders, J. Clin. Psychiatry 54(1) (1993) 13-20.	1	

*EXAMINER: Initial if reference considered, whether or not clistion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner	101	Date	<i></i>	ì
Signature	11/10/04911/	1 1 ~ /	1701	Λ (
Oliginature 1	100000	Considered /	1441	0)